Jensen, Lene

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 510

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

Jensen, L., Helleberg, H., Roffel, A., van Lier, J. J., Bjørnsdottir, I., Pedersen, P. J., Rowe, E., Derving Karsbøl, J., & Pedersen, M. L. (2017) · European Journal of Pharmaceutical Sciences

Diabetes Treatment and ManagementPharmacogenetics and Drug Metabolism

Cited by 182

Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology

Reproductive Health and ContraceptionPharmacogenetics and Drug Metabolism

Cited by 175

Effect of once‐weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo‐controlled, double‐blind, crossover trial

Korsatko, S., Jensen, L., Brunner, M., Sach‐Friedl, S., Tarp, M. D., Holst, A. G., Heller, S. R., & Pieber, T. R. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 29

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 28